Medmastery's Cardiology Digest

Medmastery

In 15 minutes or less, keep up to date on the latest studies and advancements in cardiology with the award-winning, leading clinical skills training platform, Medmastery! We’re recommended by the British Medical Association, and hundreds of thousands of clinicians around the world trust us to simplify complex information. We make it bite-sized, and easy to fit into your daily routine! In the complex and rapidly evolving field of cardiology, with new treatments and technologies emerging all the time, it can be tough to keep up with all the papers published on a daily basis. That's where our Cardiology Digest comes in. Our cardiology experts select the most important papers. Then we break them down into easy-to-understand, digestible nuggets that help you stay informed and empowered to make the right decisions for your patients. From heart disease to arrhythmias, we cover a range of topics—including cutting-edge diagnostic tools and treatment options—that are relevant to the field. So, if you're looking for a simple, accessible way to stay up to date with the latest trends and advancements in cardiology and medicine, tune in to Medmastery's Cardiology Digest! Visit us at www.medmastery.com! read less
Health & FitnessHealth & Fitness

Episodes

#9:  A primary mechanism behind decompression illness, cognitive repercussions of a myocardial infarction, and high-sensitivity cardiac troponin I (hs-cTnI) for risk-stratification of coronary artery disease
4d ago
#9: A primary mechanism behind decompression illness, cognitive repercussions of a myocardial infarction, and high-sensitivity cardiac troponin I (hs-cTnI) for risk-stratification of coronary artery disease
Our latest episode dissects three groundbreaking studies that are reshaping our understanding of the heart and its intricate connections to the body and mind.   STUDY #1: First, we explore the potential of high-sensitivity cardiac troponin I (hs-cTnI) in risk-stratifying patients with known coronary artery disease. While current guidelines don't yet recommend these tests, could there be untapped value in using troponin concentration as a preventive treatment guide? Join us as we explore the intriguing possibilities and implications presented in this study from the Journal of the American College of Cardiology. Wereski, R, Adamson, P, Daud, NSS, et al. 2023. High-sensitivity cardiac troponin for risk assessment in patients with chronic coronary artery disease. J Am Coll Cardiol. 6: 473–485. (https://doi.org/10.1016/j.jacc.2023.05.046)   STUDY #2: Next, we shift our focus to the brain-heart connection. Ever wondered about the cognitive repercussions of a myocardial infarction (MI)? This study from JAMA Neurology sheds light on the potential cognitive consequences of an MI.  Johansen, MC, Ye, W, Gross, A, et al. 2023. Association between acute myocardial infarction and cognition. JAMA Neurol. 7: 723–731. (https://doi.org/10.1001/jamaneurol.2023.1331)   STUDY #3: Third, we dive deep (pun intended!) into decompression illness. Certain divers might want to reconsider their next dive because a recent Annals of Internal Medicine study suggests a primary mechanism behind decompression illness that could change the way we perceive diving risks. What are the implications for those passionate about the deep blue? Lee, H-J, Lim, DS, Lee, J, et al. 2023. Decompression illness in divers with or without patent foramen ovale: A cohort study. Ann Intern Med. 7: 934–939. (https://doi.org/10.7326/M23-0260)   Don't miss out on these captivating discussions. Listen in to stay at the forefront of cardiology insights and to satiate your curiosity about these studies' findings. We promise, it's a heartbeat away from being your favorite episode yet! For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#8: Re-evaluating Aspirin, the amiodarone enigma, and are there health benefits to being a 'weekend warrior'?
Feb 14 2024
#8: Re-evaluating Aspirin, the amiodarone enigma, and are there health benefits to being a 'weekend warrior'?
Our latest episode of Cardiology Digest delves into some of the most intriguing and thought-provoking recent studies in the realm of heart health. Here's a sneak peek into what awaits you:   STUDY #1: We have the Amiodarone Enigma: An observational study in the Annals of Internal Medicine has brought up some concerns regarding the use of amiodarone in patients with heart failure, coronary disease, and renal failure. But is everything as it seems? Dive into the nuances of this study with us, as we explore whether the observed excess bleeding is truly due to the drug, or the elevated bleeding risk in these patients. Is it time to change our practice or do we need more compelling evidence? Ray WA et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: A retrospective cohort study. Ann Intern Med 2023 Jun; 176:769. (https://doi.org/10.7326/M22-3238)   STUDY #2: We re-evaluate Aspirin for older patients, thanks to the ASPREE study that was recently published in JAMA Network Open. It looks like it’s time to reassess our recommendations and consider whether we’re truly informed about the pros and cons of aspirin as a risk-reduction strategy.  Cloud GC et al. Low-dose aspirin and the risk of stroke and intracerebral bleeding in healthy older people: Secondary analysis of a randomized clinical trial. JAMA Netw Open 2023 Jul 3; 6:e2325803. (https://doi.org/10.1001/jamanetworkopen.2023.25803)   STUDY #3: Lastly, we find out if there are health benefits to being a “weekend warrior”. Have you ever had patients question the health benefits of their active weekends? This study from JAMA sheds light on the potential importance of exceeding the 150-minute weekly threshold of moderate-to-vigorous physical activity. But just how beneficial is it? Tune in to find out! Khurshid S et al. Accelerometer-derived “weekend warrior” physical activity and incident cardiovascular disease. JAMA 2023 Jul 18; 330:247. (https://doi.org/10.1001/jama.2023.10875)   Join us in this episode as we dissect these studies, offering insights and sparking discussions that could reshape our understanding of cardiology. Don't miss out on this enlightening journey!  For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#7: Post-stroke DOACs, SGLT-2 inhibitors and hematocrit, post-discharge rivaroxaban for COVID-19, plus the influence of age on statin efficacy
Jan 30 2024
#7: Post-stroke DOACs, SGLT-2 inhibitors and hematocrit, post-discharge rivaroxaban for COVID-19, plus the influence of age on statin efficacy
Welcome to the latest episode of Cardiology Digest, where we dive into the pressing questions of today's medical research. Here's a glimpse of what's to come:   STUDY #1: Have you ever wondered about the optimal timing for introducing DOACs (direct-acting oral anticoagulants) after strokes due to atrial fibrillation? This New England Journal of Medicine study dives into the potential advantages of early DOAC introduction. You might be surprised at the rates of symptomatic intracranial hemorrhage. But remember, patient profiles vary—for example, what works for those with mild neurologic deficits might not hold true for everyone. Fischer, U, Koga, M, Strbian, D, et al. 2023. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 26: 2411–2421. (https://doi.org/10.1056/NEJMoa2303048)   STUDY #2: Next, we’ll take a look at the curious case of rising hematocrit in certain chronic kidney disease patients who have anemia and were treated with SGLT-2 inhibitors. Did they have a genuine improvement in anemia or was it merely an illusion? SGLT-2 inhibitors are the focal point, and we'll dissect their multifaceted effects that may be at play here.  Koshino, A, Schechter, M, Chertow, GM, et al. 2023. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid.  6. (https://doi.org/10.1056/EVIDoa2300049)   STUDY #3: Hospitalization due to COVID-19 has presented a conundrum regarding post-discharge thromboprophylaxis. With the pandemic making such profound impacts on global health, it's crucial to address these concerns. See how new findings align with prior observational studies, and where rivaroxaban fits into all of this. Wang, TY,  Wahed, AS, Morris, A, et al. 2023. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med. 4: 515–523. (https://doi.org/10.7326/M22-3350)   STUDY #4: Cholesterol management remains pivotal in cardiac care. But the question our fourth study poses is this: do age differences impact the effectiveness of statins, particularly in lowering LDL cholesterol? A dive into this study could reshape perceptions on dosage recommendations for certain patient demographics. Corn, G, Melbye, M, Hlatky, MA, et al. 2023. Association between age and low-density lipoprotein cholesterol response to statins: A Danish nationwide cohort study. Ann Intern Med. 8: 1017–1026. (https://doi.org/10.7326/M22-2643)   So, arm yourself with your favorite beverage and comfy earphones, and join us in uncovering the gems these studies hold. The revelations might just change the way you see these medications and treatments! 🎧🔍📚 For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#6: Transcatheter mitral valve repair, DOACs for endoscopy, ablation for paroxysmal atrial fibrillation, Brugada syndrome
Jan 16 2024
#6: Transcatheter mitral valve repair, DOACs for endoscopy, ablation for paroxysmal atrial fibrillation, Brugada syndrome
Welcome to the latest episode of Medmastery’s Cardiology Digest, where we keep you up-to-date in the ever-evolving world of cardiology. This episode promises to be a riveting exploration of breakthrough studies!   STUDY #1: First, we'll delve into a national registry study on transcatheter mitral valve repair in a population that’s different from what the approval was initially based upon. We'll discuss the study's implications, as we eagerly await additional trials comparing this method to traditional surgery. Makkar, RR, Chikwe, J, Chakravarty, T, et al. 2023. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA. 20: 1778–1788. (https://doi.org/10.1001/jama.2023.7089)   STUDY #2: Next, we turn our attention to a ground-breaking study examining a standardized periprocedural management strategy using direct-acting oral anticoagulants for patients undergoing endoscopy. Given the study's complication rates and length of the anticoagulant interruption period, this novel approach may redefine standards for patients with atrial fibrillation.  Hansen-Barkun, C, Martel, M, Douketis, J, et al. 2023. Periprocedural management of patients with atrial fibrillation receiving a direct oral anticoagulant undergoing a digestive endoscopy. Am J Gastroenterol. 5: 812–819. (https://doi.org/10.14309/ajg.0000000000002076)   STUDY #3: Our third study puts the spotlight on the challenging mission to enhance the success rate for paroxysmal atrial fibrillation treatment. We'll explore whether wider-area ablation proved superior to standard ablation for reducing recurrence, contrast that to previous trials, and touch on what’s most important when considering the reasoning behind the choice of wider-area ablation versus standard ablation. Nair, GM, Birnie, DH, Nery, PB, et al. 2023. Standard vs augmented ablation of paroxysmal atrial fibrillation for reduction of atrial fibrillation recurrence: The AWARE randomized clinical trial. JAMA Cardiol. 5: 475–483. (https://doi.org/10.1001/jamacardio.2023.0212)   STUDY #4: Lastly, we dissect a study centered on epicardial ablation for patients with Brugada syndrome who are suffering from ventricular fibrillation. Could this burgeoning therapy eventually replace the current implantable cardioverter–defibrillator approach? Nademanee K et al. Long-term outcomes of Brugada substrate ablation: A report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry). Circulation 2023 Mar 24; [e-pub]. (https://doi.org/10.1161/CIRCULATIONAHA.122.063367)   Join us as we unravel the complexities and potential game-changers these studies offer, and embark on a journey to better understand the future landscape of cardiology. Tune in and learn with Medmastery’s Cardiology Digest! For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#5: Home blood pressure device accuracy, prognostic value of ambulatory blood pressure, and apixaban versus warfarin for On-X mechanical aortic valves
Jun 12 2023
#5: Home blood pressure device accuracy, prognostic value of ambulatory blood pressure, and apixaban versus warfarin for On-X mechanical aortic valves
Welcome to another episode of Medmastery’s Cardiology Digest! Today, we're diving into three fascinating studies that have stirred up a bit of chatter in the medical world. So grab your coffee and let's delve right in!   STUDY #1: First, we dig into a study that issues a wake-up call about the potential accuracy of home blood pressure measurements. A dash of detective work is required here that could be the key to solving the mystery of some blood pressure anomalies. Cue suspenseful music! Picone DS et al. Availability, cost, and consumer ratings of popular nonvalidated vs validated blood pressure–measuring devices sold online in 10 countries. JAMA 2023 May 2; 329:1514. (https://doi.org/10.1001/jama.2023.2661)   STUDY #2: Our second study takes a close look at 24-hour ambulatory blood pressure measurement and its prognostic value. It’s a robust study, but doesn't shy away from addressing some thorny issues surrounding the use of ambulatory monitoring in the U.S. Does this comprehensive blood pressure monitoring lead to better clinical outcomes? This is sure to spark some debate! Staplin N et al. Relationship between clinic and ambulatory blood pressure and mortality: An observational cohort study in 59 124 patients. Lancet 2023 May 5; [e-pub]. (https://doi.org/10.1016/S0140-6736(23)00733-X)   STUDY #3: Lastly, we explore a paper that evaluates whether apixaban, a commonly prescribed oral anticoagulant, had a higher rate of thromboembolic events than warfarin when given to patients with On-X mechanical aortic valves. Tune in as we explore the implications of this eye-opening research!. Wang TY et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023 May 6; [e-pub]. (https://doi.org/10.1056/EVIDoa2300067)   Join us for this informative overview of contemporary research, as we break down complex medical concepts into digestible nuggets of knowledge, suitable for both medical students and healthcare professionals eager to keep up-to-date in cardiology. For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#4: AI vs. doctors on Reddit, hypertension strategies in surgery, and iron's role in heart failure: Unpacking recent medical breakthroughs
May 17 2023
#4: AI vs. doctors on Reddit, hypertension strategies in surgery, and iron's role in heart failure: Unpacking recent medical breakthroughs
Welcome to another enlightening episode of our podcast, where we delve into the latest medical research to bring you insights that can enhance your understanding and practice. This episode focuses on four intriguing studies: STUDY #1: We begin with a fascinating study comparing the responses of an AI chatbot and physicians to medical questions posted on a Reddit forum. The results might surprise you and prompt a rethink on how AI can assist in routine physician duties. Ayers JW et al. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. JAMA Intern Med 2023 Apr 28; [e-pub]. (https://doi.org/10.1001/jamainternmed.2023.1838)   STUDY #2: Next, we delve into the POISE-3 trial, which examined the effects of hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery. The findings could have significant implications for the management of patients with hypertension undergoing surgery. Marcucci M et al. Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: An international randomized controlled trial. Ann Intern Med 2023 Apr 25; 176:605. (https://doi.org/10.7326/M22-3157)   STUDY #3: Our third study is the IRONMAN trial, which investigated the effects of intravenous ferric derisomaltose in patients with heart failure and iron deficiency. The results provide further support for the benefit of iron repletion in this population. Kalra PR et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022 Dec 17; 400:2199. (https://doi.org/10.1016/S0140-6736(22)02083-9)   STUDY #4: Finally, we discuss a subgroup analysis of the AFFIRM-AHF trial, exploring the association between hemoglobin levels and the efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency. The findings shed light on the role of hemoglobin levels in the treatment outcomes of these patients. Filippatos G et al. Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: An AFFIRM-AHF subgroup analysis. Circulation 2023 Apr 13; [e-pub]. (https://doi.org/10.1161/CIRCULATIONAHA.122.060757)   This episode promises to be a treasure trove of knowledge, offering insights into the role of AI in medicine, the management of hypertension in surgery, the importance of iron repletion in heart failure, and the influence of hemoglobin levels on treatment outcomes. So, grab your headphones and join us as we navigate these captivating studies. Don't miss this opportunity to enhance your understanding and make a difference in patients' lives. See you there! For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
#3: Abbreviated antiplatelet therapy, COVID-19 and ECG changes, plus AI-generated medical advice
May 9 2023
#3: Abbreviated antiplatelet therapy, COVID-19 and ECG changes, plus AI-generated medical advice
Welcome to Episode 3 of Medmastery's Cardiology Digest, where we bring you expert insights and the latest scientific findings in the field of cardiology. Stay updated with our bite-sized summaries of late-breaking trials. Hit the subscribe button so you never miss an important update again.   In today's episode, we'll discuss four studies that shed light on new developments in cardiology and medicine:   STUDY 1: The final 15-month results of the MASTER-DAPT trial by Landi A et al. show that abbreviated antiplatelet therapy is non-inferior to standard antiplatelet therapy for high bleeding risk patients undergoing percutaneous coronary intervention (PCI). The trial found that abbreviated therapy significantly reduced the risk of bleeding, with no increase in the risk of ischemic events. Landi A et al. Abbreviated or standard antiplatelet therapy in HBR patients: Final 15-month results of the MASTER-DAPT trial. JACC Cardiovasc Interv 2023 Apr 10; 16:798. (https://doi.org/10.1016/j.jcin.2023.01.366)   STUDY 2: The prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players is discussed in a recent study by Bhatia RT et al. The study found that over 20% of the players had de-novo ECG changes, which were associated with myocardial inflammation and fibrosis. The authors recommend routine ECG screening for athletes post-COVID-19 infection. Bhatia RT et al. Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players. Heart 2023 Mar 27; [e-pub]. (https://doi.org/10.1136/heartjnl-2022-322211)   STUDY 3: Haupt CE and Marks M discuss the benefits, limits, and risks of AI-generated medical advice in their recent JAMA article. They argue that AI-generated advice has the potential to improve clinical decision-making and reduce errors, but highlight the need for appropriate training, validation, and regulation to ensure patient safety. Haupt CE, Marks M. AI-Generated Medical Advice-GPT and Beyond. JAMA. 2023 Apr 25;329(16):1349-1350. doi: 10.1001/jama.2023.5321. PMID: 36972070.   Study 4: Lee P et al. discuss the benefits, limits, and risks of GPT-4 as an AI chatbot for medicine in their recent NEJM article. They note that while GPT-4 has the potential to improve patient education and communication, it also raises concerns around privacy, liability, and bias. The authors highlight the need for further research and guidelines on the use of AI chatbots in healthcare. Lee P, Bubeck S, Petro J. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. N Engl J Med. 2023 Mar 30;388(13):1233-1239. doi: 10.1056/NEJMsr2214184. PMID: 36988602.   Thanks for listening to Medmastery's Cardiology Digest. Join us next week for more expert insights and scientific updates and visit https://www.medmastery.com/podcasts/cardiology-podcast for more information.
#1: Caffeine's cardiac impact, cardiologists' financial ties, hidden CAD dangers, and sotatercept news
Apr 26 2023
#1: Caffeine's cardiac impact, cardiologists' financial ties, hidden CAD dangers, and sotatercept news
Welcome to another exciting podcast episode, where we dive into the latest cardiovascular research! Join us as we discuss four fascinating studies: STUDY #1: Discover how subclinical coronary atherosclerosis detected by computed tomographic angiography (CTA) can pose a significant risk for myocardial infarction (MI) in asymptomatic middle-aged men and women in a Danish cohort. Fuchs A et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: A prospective observational cohort study. Ann Intern Med 2023 Mar 28; [e-pub]. (https://doi.org/10.7326/M22-3027) STUDY #2: We'll examine the Open Payments Program (OPP) data, revealing trends in industry payments to cardiologists from 2014 to 2019, including the necessity for transparency. Zhang R et al. Trends in industry payments to cardiologists from 2014 to 2019. Circ Cardiovasc Qual Outcomes 2023 Mar 17; [e-pub]. (https://doi.org/10.1161/CIRCOUTCOMES.122.009820) STUDY #3: In this randomized case-crossover study, we'll explore whether caffeinated coffee affects premature atrial contractions (PACs) and ventricular contractions (PVCs) in healthy adults. Marcus GM et al. Acute effects of coffee consumption on health among ambulatory adults. N Engl J Med 2023 Mar 23; 388:1092. (https://doi.org/10.1056/NEJMoa2204737) STUDY #4: Lastly, we'll discuss a phase 3 trial of sotatercept, a potential new class of therapy for pulmonary arterial hypertension (PAH), focusing on its effects on 6-minute walk distance and other secondary endpoints. Hoeper MM et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023 Mar 6; [e-pub]. (https://doi.org/10.1056/NEJMoa2213558) This episode promises to be a wealth of knowledge and insights into cardiovascular health. So, get comfortable, grab your headphones, and let's dive into these captivating studies to uncover the secrets to a healthier heart. Enhance your understanding and make a difference in patients' lives. See you there! For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.